RHT Shares Resonance Health Limited
ASX · ASXLast in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Imaging-platform adoption and improving momentum support scalable diagnostic growth.
Future value: $0.10 (+21.95%) · 6-12 months
Signal breakdown
- ▸Strong 90-day momentum and commercial progress.
- ▸Above 50-day MA (+23.64%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 2.34× average — accumulation
- ▸Near 52-week high (92.2% of range) — strength
- ▸~22% upside to price target
Is RHT a buy right now?
Trend: RHT is trading above the 50-day average (+2.86%), RSI 51 — neutral momentum, with a 3-month return of +24.14%.
Valuation & quality: Resonance Health Limited trades on PEG 2.55, price-to-book 3.13; fundamentals show net margin 9.6%, return on equity 14.8%, revenue growth 32.7% year on year.
Our screen: STRONG BUY (score 6) — Imaging-platform adoption and improving momentum support scalable diagnostic growth.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -20.00% | +25.00% | -20.00% | +0.00% | +50.00% | +0.00% | +16.70% | +0.00% |
Fundamentals
Technical signals
About Resonance Health Limited
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments.
Sector: Healthcare · Industry: Health Information Services · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.